Merrimack Pharmaceuticals, Inc.
http://www.merrimackpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merrimack Pharmaceuticals, Inc.
Chinese Biotech Financing Rebounds But Mega Deals Missing
Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
Ipsens Onivyde Pancreatic Cancer Trial Survival Disappointment Dashes Sales Boost Hopes
The French firm unveiled data from its pancreatic cancer trial showing Onivyde plus chemotherapy improved median PFS by just over a month compared with current treatment of choice but failed to beat its overall survival benchmark.
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Liposomes
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Hermes Biosciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice